Pharmacovigilance Market Overview, Share & Trends Analysis, 2026-2034
REPORT DETAILS
REPORT DETAILS
ABOUT THIS REPORT
Pharmacovigilance Market Summary
The global pharmacovigilance market was valued at USD 9.50 billion in 2025. The market is projected to grow at a CAGR of 8.9% from 2026 to 2034. Increased regulatory focus and growing drug safety monitoring needs are boosting the market.
Market Statistics
Key Takeaways
- North America led with a 40.6% revenue share in 2025. This is owing to the presence of major pharmacovigilance companies in the region.
- Asia Pacific is projected to register a significant CAGR of 10.1%. The expansion and M&A of major companies drives the regional market growth.
- The market in Japan is projected to witness rapid growth at a 9.7% CAGR. This is due to increased prevalence of chronic diseases.
- The oncology segment held the largest revenue share of 31.8% in 2025. Pharmacovigilance in oncology helps prevent and manage drug-induced adverse reactions.
- The pharmaceutical companies segment is projected to exhibit a significant CAGR of 9.4%. This is due to an increase in drug innovation by pharma firms
Industry Dynamics
- The increasing outsourcing of pharmacovigilance services to by pharma firms to comply with stringent regulatory requirements is driving market demand.
- The adoption of advanced technologies such as AI and machine learning in pharmacovigilance is shaping the market landscape.
- Rising partnerships among pharma and biotech companies with CROs is creating several market opportunities.
- High implementation costs of advanced monitoring is creating several market opportunities.
AI Impact on Pharmacovigilance Market
- Artificial Intelligence contributes to enhancing the monitoring of safety by efficiently evaluating high volumes of adverse events data.
- It enables rapid identification of safety issues that may arise following market release.
- AI enhances efficiency in workflow by streamlining case evaluation, reporting, and data analysis activities.
- It assists healthcare organizations in making effective safety decisions using predictive models.
Pharmacovigilance is the study of detecting, assessing, and preventing adverse effects of medicine. Although medicines and vaccines are subjected to various testing for safety and efficacy in clinical trials before approval, these trials involve a limited number of patients over a relatively short duration. Increased research and development activities and new drug approvals are major growth drivers for the pharmacovigilance market. For instance, in 2022, according to the UNESCO Institute for Statistics (UIS), global research and development (R&D) expenditure amounted to USD 2.5 trillion, reflecting a 5.43% surge compared to the previous year. Increase of clinical trials and new drug approval, leading to an increased need for pharmacovigilance during drug development. Therefore, with these advancements in new drug approval and research and development, the growth of the pharmacovigilance market is being propelled.
To Understand More About this Research: Download Sample Report
The pharmacovigilance market is driven by increasing drug consumption and adverse drug reactions (ADRs). Global rise in drug consumption, particularly due to the aging population and the prevalence of chronic diseases, is leading to more cases of adverse drug reactions and has driven market growth. For instance, according to the Food and Drug Administration's Adverse Event Reporting System (FAERS), in 2022, more than 1.25 million severe cases of adverse drug reactions were reported in the U.S. ADRs (adverse drug reactions) lead to increased morbidity, mortality, hospitalizations, and healthcare costs. With a rise in global drug consumption and the incidence of ADRs, there is a growing need for pharmacovigilance systems to monitor, detect, and manage these adverse events. Therefore, an increase in adverse drug reactions (ADRs) is driving the market growth.
Pharmacovigilance vs Drug Safety Monitoring
| Aspect | Pharmacovigilance | Drug Safety Monitoring |
| Coverage | Widely encompassing process of detecting, assessing, preventing, and managing risks associated with drugs | Covers monitoring of adverse drug reactions and their side effects |
| Life Cycle Coverage | Covers the full life cycle of drugs – starting from clinical trials through to post-market surveillance | Mainly covers post-marketing and ongoing treatment phase |
| Major Purpose | Guarantees patient safety and adherence to regulatory requirements | Detects and monitors adverse reactions to drugs |
| Incorporated Activities | Signal detection, risk management, regulatory reporting, data analytics, and safety communications | Collecting, monitoring, and reporting adverse reactions to drugs |
| Regulatory Aspect | Highly related to international regulations and compliance rules | Related to safety reporting with a compliance angle |
| Technologies Involved | Involves artificial intelligence, analytics, automation, EHR mining, cloud pharmacovigilance technology | Primarily relies on adverse reaction reporting technology |
Pharmacovigilance Market Drivers and Trends
Increased Outsourcing of Pharmacovigilance Services
Pharmaceutical companies are increasingly outsourcing pharmacovigilance services to comply with stringent regulatory requirements. Global health authorities including the Food and Drug Administration (FDA) and European Medicines Agency (EMA), enforce more rigorous safety standards. Also, companies must implement pharmacovigilance systems to ensure their products remain compliant throughout their lifecycle. For instance, in September 2021, IQVIA Holdings announced a collaboration with NRx Pharmaceuticals (NRXP) to provide pharmacovigilance services and medical information. This collaboration aims to support the emergency use authorization of ZYESAMI (a pre-commercial drug being investigated for COVID-19-associated respiratory failure) by facilitating pharmacovigilance and medical information programs.
Adoption of Advanced Technologies
The integration of artificial intelligence (AI), machine learning, and big data analytics in pharmacovigilance has enhanced safety monitoring capabilities for companies. These technologies facilitate the rapid processing of safety data volumes, leading to enhanced accuracy and efficiency in pharmacovigilance operations. For instance, in December 2021, Roche and Genentech collaborated with Recursion Pharmaceuticals to investigate novel domains in cell biology and create new therapies in critical areas of neuroscience and oncology. The alliance will harness Recursion's technology-driven drug discovery platform and Roche single-cell data generation and machine learning (ML) capabilities to comprehensively identify new drug targets and accelerate the development of small molecule medications. Genentech and Roche are using machine learning (ML) techniques across various disease areas and therapeutic modalities to develop more advanced models for drug discovery. Consequently, technological advancement is improving the efficiency and accuracy of pharmacovigilance processes, driving market growth.
Pharmacovigilance Market Segment Insights
Pharmacovigilance Market Breakdown by Therapeutic Area Insights
The global pharmacovigilance market segmentation, based on therapeutic area, includes oncology, neurology, cardiology, respiratory systems, and others. The oncology segment held the largest revenue share of the market due to the side effects of cancer therapy being one of the most important issues faced by cancer patients during their illness. Pharmacovigilance in oncology helps to prevent, detect, and manage drug-induced adverse reactions. For instance, according to the World Health Organization (WHO), in 2022, there were nearly 20 million new cancer cases reported worldwide, leading to 9.7 million cancer-related deaths. Among these cases, lung cancer was the most commonly occurring cancer, with 2.5 million new cases accounting for 12.4% of the total new cancer cases globally. Increase in the number of cancer cases leads to an increased need for pharmacovigilance to study the side effects of drugs on oncology patients.
Pharmacovigilance Market Breakdown by End-Use Insights
The global pharmacovigilance market segmentation, based on end use, includes pharmaceutical companies, biotechnology companies, medical device manufacturers, and others. The pharmaceutical companies segment is projected to exhibit a significant CAGR in the global market due to the increase in drug innovation by pharmaceutical companies. For instance, in 2022, the Center for Drug Evaluation and Research (CDER) approved 37 new drugs, with 28 of them receiving approval after their first review cycle. Pharmacovigilance is crucial in facilitating drug innovation, spanning from the pre-approval phase to the post-marketing stage.
Pharmacovigilance Regional Insights
By region, the study provides the pharmacovigilance market insights into North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa. North America accounted for the largest revenue share in the global pharmacovigilance market due to the presence of major pharmacovigilance companies in the region and rising investment in research and development. For instance, in 2023, the Center for Drug Evaluation and Research (CDER) approved 55 novel drugs in the region. Thus, the rise in the number of new drug approvals and the presence of major pharmacovigilance companies in the region is driving market growth, thereby contributing to the dominance of North America in the global market.
The Asia Pacific region is projected to register a substantial CAGR over the forecast period due to the expansion and merger and acquisition of companies in the region is driving market growth. For instance, in May 2023, Labcorp Laboratory Corporation of America Holdings announced an expansion project for its CB Trial Laboratory in collaboration with BML Research Institute and General Laboratory in Japan. The expanded laboratory will offer additional dedicated space to facilitate global clinical trials managed by Labcorp. Thus, such expansion and merger and acquisitions are fuelling the pharmacovigilance market in the Asia Pacific region.
The pharmacovigilance market in Japan is expected to have significant growth due to the increased prevalence of chronic diseases, elevated drug usage, and growing occurrence of adverse drug reactions (ADRs). For instance, Nextrove founded a subsidiary in Tokyo in August 2020 to enhance support for current and prospective partners and clients. The company offers consulting services to assist Japanese pharmaceutical firms with pharmacovigilance and other pertinent challenges.
Data Privacy and Cybersecurity in Pharmacovigilance
Since pharmacovigilance systems involve many patient records, trial data, and adverse event reports that contain confidential information, data security and cybersecurity are of great importance to both the company and the healthcare sector. The use of cloud computing, AI analytics, and digital reporting has necessitated that companies focus on secure cloud computing platforms, cryptography, and cybersecurity measures for protecting any sensitive data. Compliance with the General Data Protection Regulation (GDPR) as well as HIPAA is becoming very significant to guarantee security and reporting of patient data in pharmacovigilance systems.
Pharmacovigilance Market Key Players & Competitive Insights
The pharmacovigilance market is a dynamic and rapidly evolving environment with several players striving to innovate and differentiate from each other. Major global companies are dominating the market by leveraging extensive research and development capabilities, advanced manufacturing technologies, and broad distribution networks to maintain a competitive edge. The players are engaged in strategic activities such as mergers and acquisitions, partnerships, and collaborations to enhance their product portfolios and expand their market presence.
Startups are contributing to the market by introducing innovative technologies and attributing them to pharmacovigilance. This competitive scenario is further intensified by ongoing advancements in biotechnology, increased focus on big data analytics, machine learning (ML), and growing demand for the pharmacovigilance market. Major players in the pharmacovigilance market include Laboratory Corporation of America Holdings; Cognizant; Thermo Fisher Scientific Inc; ICON plc.; Accenture; IQVIA; Aris Global; IBM Corporation; United BioSource LLC; PAREXEL International Corporation; TAKE Solutions; and Pharmaceutical Development Group, Inc.
IQVIA is a provider of advanced analytics, technology solutions, and clinical research services to the life sciences industry. It creates connections across all aspects of healthcare through its analytics, transformative technology, big data resources, and extensive domain expertise. IQVIA, with approximately 86,000 employees, conducts operations in more than 100 countries. For instance, in October 2023, IQVIA announced a collaboration with Argenx to enhance the treatment options for patients with rare autoimmune diseases using advanced technology-enabled pharmacovigilance safety services and solutions with a focus on rapidly expanding clinical development and commercialization efforts for new indications.
Parexel, a clinical research organization (CRO), with headquarters based in Durham, North Carolina, offers comprehensive Phase I to IV clinical development services, regulatory and product development consulting, eClinical solutions, patient and site recruitment, medical device consulting, pharmacovigilance, biotechnology, and biotech with a team of over 21,000 global professionals. Parexel collaborates with biopharmaceutical industry leaders, emerging innovators, and research sites to strategize and execute patient-centric clinical trials. For instance, in February 2023, Parexel International Corporation introduced the Expert Series–New Medicines, Novel Insights. The series focuses on the increasing personalization and precision of advanced medicines within the therapeutic landscape, as well as the growing complexity of the drug development process. Through the New Medicines, Novel Insights research series, Parexel aims to provide expert-led guidance to facilitate patient-focused drug development and expedite the delivery of impactful treatments to patients.
List of Key Companies in Pharmacovigilance Market
- Laboratory Corporation of America Holdings
- Cognizant
- Thermo Fisher Scientific Inc
- ICON plc
- Accenture
- IQVIA
- Aris Global
- IBM Corporation
- United BioSource LLC
- PAREXEL International Corporation
- TAKE Solutions
- Pharmaceutical Development Group Inc.
Pharmacovigilance Industry Developments
April 2026: The FDA made ICH E2B(R3) format mandatory for all Individual Case Safety Report (ICSR) submissions through its Electronic Submissions Gateway (ESG). This move significantly overhauled how companies electronically transmit drug safety data. (source: fda.gov)
January 2026: United BioSource LLC (UBC) announced the acquisition of Evidinno Outcomes Research. According to UBC, the acquisition is aimed at expanding its health economics and real-world evidence (RWE) capabilities. (source: ubc.com)
Pharmacovigilance Market Segmentation
By Service Outlook
- In-house
- Contract Sourcing
By Product Life Cycle Outlook
- Pre-clinical
- Phase I
- Phase II
- Phase III
- Phase IV
By Type Outlook
- Spontaneous Reporting
- Intensified ADR Reporting
- Targeted Spontaneous Reporting
- Cohort Event Monitoring
- EHR Mining
By Process Flow Outlook
- Case Data Management
- Case Logging
- Case Data Analysis
- Medical Reviewing and Reporting
- Signal Detection
- Adverse Event Logging
- Adverse Event Analysis
- Adverse Event Review & Reporting
- Risk Management System
- Risk Evaluation System
- Risk Mitigation System
BY Therapeutic Area Outlook
- Oncology
- Neurology
- Cardiology
- Respiratory Systems
- Others
By End-Use Outlook
- Pharmaceuticals
- Biotechnology Companies
- Medical Device Manufacturers
- Others
By Regional Outlook
- North America
- US
- Canada
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Netherlands
- Russia
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- Malaysia
- South Korea
- Indonesia
- Australia
- Rest of Asia Pacific
- Middle East & Africa
- Saudi Arabia
- UAE
- Israel
- South Africa
- Rest of Middle East & Africa
- Latin America
- Mexico
- Brazil
- Argentina
- Rest of Latin America
Pharmacovigilance Report Scope
| Report Attributes | Details |
| Market Size Value in 2025 | USD 9.50 billion |
| Market Size Value in 2026 | USD 9.87 billion |
| Revenue Forecast in 2034 | USD 20.10 billion |
| CAGR | 8.90% from 2026 to 2034 |
| Base Year | 2025 |
| Historical Data | 2021 – 2024 |
| Forecast Period | 2026 – 2034 |
| Quantitative Units | Revenue in USD billion and CAGR from 2026 to 2034 |
| Report Coverage | Revenue Forecast, Market Competitive Landscape, Growth Factors, and Trends |
| Segments Covered |
|
| Regional Scope |
|
| Competitive Landscape |
|
| Report Format |
|
| Customization | Report customization as per your requirements with respect to countries, regions, and segmentation. |
FAQ's
The global pharmacovigilance market size was valued at USD 9.50 billion in 2025 and is projected to grow to USD 20.10 billion by 2034.
The global market is projected to register a CAGR of 8.90% during the forecast period, 2026-2034.
North America had the largest share of the global market
The key players in the market are Laboratory Corporation of America Holdings; Cognizant; Thermo Fisher Scientific Inc; ICON plc.; Accenture; IQVIA; Aris Global; IBM Corporation; United BioSource LLC; PAREXEL International Corporation; TAKE Solutions; and Pharmaceutical Development Group, Inc
The oncology segment is anticipated to experience substantial growth with a significant CAGR in the global market due to increasing prevalence of cancer cases.
The pharmaceutical companies segment accounted for a significant revenue share of the market in 2025 due to the increase in drug innovation by pharmaceutical companies.
Download Sample Report of Pharmacovigilance Market Overview, Share & Trends Analysis, 2026-2034
Please fill out the form to request a customized copy of the research report.
